论文部分内容阅读
目的:研究CEA、NSE、CYFRA21-1在肺癌不同分期及治疗前后的水平变化。方法:本研究中所有研究对象均来自东营市人民医院确诊为肺癌的患者,共121例。早期未治疗肺癌患者35例;晚期未治疗肺癌患者30例;经过治疗的肺癌患者56例;肺良性疾病组50例;健康对照组100例。分别对这几组研究对象血清中CEA、NSE、CYFRA21-1水平进行检测。用SPSS17.0统计分析软件进行统计学分析。结果:采用电化学发光法对65例未治疗肺癌患者血清中CEA、NSE、CYFRA21-1进行检测后发现,肺癌患者血清中三者水平均有不同程度的增高,显著高于肺良性疾病组和健康对照(P<0.05);肺良性疾病患者血清中三者指标与健康对照相比无显著性差异(P>0.05)。经过对晚期肺癌患者血清中CEA、NSE、CYFRA21-1进行检测发现,晚期肺癌患者三者血清中水平显著升高,早期未治疗肺癌患者血清中三者水平也部分升高,但是显著低于晚期未治疗肺癌组(P<0.05)。经过治疗的肺癌患者血清中CEA、NSE、CYFRA21-1水平与肺良性疾病组和健康对照组相比无显著性差异(P>0.05),较肺癌未治疗组相比水平显著下降(P<0.05)。结论:1.肺癌晚期患者CEA、NSE、CYFRA21-1水平显著升高。2.治疗后CEA、NSE、CYFRA21-1水平显著下降。
Objective: To study the changes of CEA, NSE and CYFRA21-1 in different stages of lung cancer and before and after treatment. METHODS: All subjects in this study were from 121 patients diagnosed with lung cancer at Dongying Municipal People’s Hospital. 35 patients with early untreated lung cancer, 30 patients with advanced untreated lung cancer, 56 patients with treated lung cancer, 50 patients with benign lung disease, and 100 healthy controls. The levels of CEA, NSE and CYFRA21-1 in serum of these groups were tested respectively. SPSS17.0 statistical analysis software for statistical analysis. Results: The serum levels of CEA, NSE and CYFRA21-1 in 65 patients with untreated lung cancer were detected by electrochemiluminescence. The results showed that the serum levels of all three in lung cancer patients increased to some extent, which were significantly higher than those in benign lung disease group and (P <0.05). There was no significant difference between the three indicators in serum of patients with benign lung diseases and healthy controls (P> 0.05). After the serum of patients with advanced lung cancer CEA, NSE, CYFRA21-1 were detected in patients with advanced lung cancer serum levels were significantly elevated in patients with early untreated lung cancer serum levels of three were also partially elevated, but significantly lower than the late Not treated lung cancer group (P <0.05). The levels of CEA, NSE and CYFRA21-1 in serum of patients with lung cancer after treatment were not significantly different from those of benign lung disease group and healthy control group (P> 0.05), but significantly lower than those of untreated lung cancer patients (P <0.05) ). Conclusions: 1. The levels of CEA, NSE and CYFRA21-1 in patients with advanced lung cancer were significantly increased. After treatment, the levels of CEA, NSE and CYFRA21-1 decreased significantly.